Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Coherus Bio (CHRS)

Coherus Bio (CHRS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,285,750
  • Shares Outstanding, K 69,764
  • Annual Sales, $ 0 K
  • Annual Income, $ -209,340 K
  • 60-Month Beta 2.90
  • Price/Sales 5.84
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.58
  • Number of Estimates 3
  • High Estimate 0.73
  • Low Estimate 0.35
  • Prior Year -0.92
  • Growth Rate Est. (year over year) +163.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.50 +18.90%
on 11/05/19
19.74 -6.64%
on 11/08/19
-0.12 (-0.65%)
since 10/11/19
3-Month
15.50 +18.90%
on 11/05/19
23.91 -22.92%
on 09/25/19
-0.18 (-0.97%)
since 08/12/19
52-Week
8.32 +121.51%
on 01/04/19
23.91 -22.92%
on 09/25/19
+7.49 (+68.39%)
since 11/12/18

Most Recent Stories

More News
Coherus BioSciences Management to Present at Two Upcoming Investor Healthcare Conferences

Coherus BioSciences, Inc. ("Coherus", Nasdaq: CHRS), today announced that senior management will present at two upcoming investor healthcare conferences.

CHRS : 18.43 (-1.97%)
The Zacks Analyst Blog Highlights: Coherus, Incyte, ACADIA and Celgene

The Zacks Analyst Blog Highlights: Coherus, Incyte, ACADIA and Celgene

ACAD : 46.33 (+2.41%)
CHRS : 18.43 (-1.97%)
CELG : 110.00 (+0.39%)
INCY : 86.14 (+1.51%)
4 Biotech Stocks That Could Keep Beating Wall Street

The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.

BMY : 58.39 (+0.41%)
LLY : 113.17 (+0.33%)
ACAD : 46.33 (+2.41%)
CHRS : 18.43 (-1.97%)
CELG : 110.00 (+0.39%)
BIIB : 291.40 (-0.93%)
INCY : 86.14 (+1.51%)
ADPT : 28.35 (+0.11%)
ALEC : 16.31 (-2.22%)
NGM : 13.00 (+1.40%)
TAK : 19.62 (-0.56%)
Coherus BioSciences Announces New Employment Inducement Grants

Coherus BioSciences, Inc. ("Coherus" or the "Company", Nasdaq: CHRS), today announced that effective November 7, 2019, the compensation committee of the Company's board of directors granted options to...

CHRS : 18.43 (-1.97%)
Coherus Bioscien has the Best Relative Performance in the Biotechnology Industry (CHRS , VNDA , ATRA , EPZM , RDUS )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

ATRA : 13.00 (-0.38%)
CHRS : 18.43 (-1.97%)
VNDA : 14.93 (+0.34%)
SmarTrend Watching for Potential Pullback in Shares of Coherus Bioscien After 3.14% Gain

Coherus Bioscien (NASDAQ:CHRS) traded in a range yesterday that spanned from a low of $17.42 to a high of $19.49. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high...

CHRS : 18.43 (-1.97%)
Coherus BioSciences (CHRS) Q3 Earnings and Revenues Surpass Estimates

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 75.00% and 19.35%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?...

CHRS : 18.43 (-1.97%)
Coherus Acquires Commercial Rights for Leading Lucentis Biosimilar in the United States

Coherus BioSciences, Inc. ("Coherus" or the "Company", Nasdaq: CHRS), today announced the Company has acquired exclusive rights from Bioeq IP AG, ("Bioeq") a Swiss biopharmaceutical joint venture, to commercialize...

CHRS : 18.43 (-1.97%)
Coherus BioSciences Reports Corporate Highlights and Third Quarter 2019 Financial Results

Coherus BioSciences, Inc. ("Coherus" or the "Company", Nasdaq: CHRS), today reviewed corporate highlights and reported financial results for the quarter ended September 30, 2019.

CHRS : 18.43 (-1.97%)
Investors Can Find Strong Stocks with our First Profit Screen

Investors Can Find Strong Stocks with our First Profit Screen

KOS : 7.48 (+2.33%)
FB : 194.47 (+2.56%)
CRSP : 53.58 (+5.24%)
CPRX : 4.91 (-2.19%)
CHRS : 18.43 (-1.97%)
BRFS : 7.94 (-4.80%)
AAPL : 261.81 (-0.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade CHRS with:

Business Summary

Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid...

See More

Key Turning Points

2nd Resistance Point 19.40
1st Resistance Point 18.92
Last Price 18.43
1st Support Level 18.03
2nd Support Level 17.62

See More

52-Week High 23.91
Last Price 18.43
Fibonacci 61.8% 17.95
Fibonacci 50% 16.11
Fibonacci 38.2% 14.28
52-Week Low 8.32

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar